AEON Biopharma Inc. has released a corporate presentation outlining its strategy to introduce ABP-450, a biosimilar to BOTOX®, into the U.S. therapeutic neurotoxin market. The company aims to achieve clinical equivalence with BOTOX® and pursue all 12 therapeutic indications currently held by the brand. ABP-450 is based on a globally validated manufacturing platform, already approved in over 69 countries and FDA-approved for aesthetics under the Jeuveau® brand. AEON Biopharma positions ABP-450 as a clinically indistinguishable alternative, seeking to enable confident switching by providers, achieve payer coverage parity, and offer a competitive option to address rising neurotoxin costs. The U.S. therapeutic neurotoxin market is projected to exceed $5 billion by 2030, with BOTOX® currently maintaining over 65% market share. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.